AstraZeneca

25 Mars 2020 08:20

AstraZeneca to discover and develop siRNA therapeutics for Cardiovascular, Renal, Metabolic and Respiratory diseases in new collaboration

Collaboration with Silence Therapeutics aims to develop novel, targeted treatments to address significant unmet need
AstraZeneca will collaborate with Silence Therapeutics to discover, develop and commercialise small interfering RNA (siRNA) therapeutics for the treatment of Cardiovascular, Renal, Metabolic and Respiratory diseases.
This multi-target collaboration will harness Silence’s estab

24 Mars 2020 09:08

AstraZeneca donerar 9 miljoner ansiktsmasker för att underlätta sjukvårdens hantering av COVID-19 över hela världen

AstraZeneca donerar nio miljoner ansiktsmasker för att stödja sjukvårdspersonal runt om i världen som hanterar den globala COVID-19 pandemin. Italien kommer få de första sändningarna av andningsmasker redan under denna vecka, och leverans till fler länder följer.

19 Mars 2020 08:01

Lynparza granted orphan drug designation in Japan for BRCA-mutated metastatic pancreatic cancer

AstraZeneca today announced that Lynparza (olaparib) has been granted orphan drug designation (ODD) in Japan for the maintenance treatment of germline BRCA-mutated (gBRCAm) curatively unresectable pancreatic cancer. Lynparza is co-developed and co-commercialised with MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada)

17 Mars 2020 08:02

Imfinzi confirmed a sustained overall survival benefit in final analysis of the Phase III CASPIAN trial in 1st-line extensive-stage small cell lung cancer

High-level results from the final analysis of the Phase III CASPIAN trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of standard-of-care (SoC) chemotherapies confirmed a sustained, clinically meaningful overall survival (OS) benefit for patients with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.

6 Mars 2020 08:02

Update on Phase III DANUBE trial for Imfinzi and tremelimumab in unresectable, Stage IV bladder cancer

The Phase III DANUBE trial for Imfinzi (durvalumab) and Imfinzi plus tremelimumab in unresectable, Stage IV (metastatic) bladder cancer did not meet the primary endpoints of improving overall survival (OS) versus standard-of-care (SoC) chemotherapy for Imfinzi monotherapy in patients whose tumour cells and/or tumour-infiltrating immune cells express high levels (≥25%) of PD-L1, or for Imfinzi

2 Mars 2020 08:01

AstraZeneca completes divestment agreement with Atnahs Pharma for established hypertension medicines

AstraZeneca today announced that it has completed the previously communicated agreement with Atnahs Pharma (Atnahs) to divest its global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination).

25 Februari 2020 08:02

AstraZeneca divests global rights to Movantik

AstraZeneca has agreed to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill). Movantik is a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for the treatment of opioid-induced constipation (OIC).

19 Februari 2020 19:36

AstraZenecas BioVentureHub och IBM samarbetar för att stärka kompetens inom digital hälsa

AstraZeneca meddelar idag att man ingått ett nytt samarbete med IBM Sverige genom BioVentureHub. Små och medelstora företag (SME) som är anslutna till IBM Sweden eller AstraZenecas BioVentureHub erbjuds nu tillgång till varandras öppna plattform för innovation.

14 Februari 2020 08:10

AstraZeneca PLC:s resultatrapport för helåret och fjärde kvartalet 2019

Ett år präglat av betydande innovation för patienter; den strategiska omvandlingen accelererar
AstraZeneca har levererat ett år med stark tillväxt, tack vare lanseringen av nya läkemedel, ytterligare framsteg i forskningsportföljen och med ett stort antal godkännanden och övergripande resultat. Dessa trender kommer att fortsätta under 2020, tillsammans med vinsttillväxt och tillväxt i likvida

29 Januari 2020 08:00

Anna-Lena Engwall ny marknadsbolagschef för AstraZeneca Nordic-Baltic

AstraZeneca meddelar i dag att man har anställt Anna-Lena Engwall som chef för AstraZenecas nordisk-baltiska marknadsbolag, hon tillträder tjänsten den 6 februari 2020.

27 Januari 2020 08:11

Phase II DESTINY-Gastric01 trial of Enhertu versus chemotherapy met primary endpoint

High-level results from the positive registrational Phase II trial DESTINY-Gastric01 showed AstraZeneca’s and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu, achieved a statistically significant and clinically meaningful improvement in objective response rate and overall survival in patients with HER2-positive unresectable or metastatic gastric or gastroesophageal junction cancer.....

27 Januari 2020 08:07

Brilinta met primary endpoint in Phase III THALES trial in stroke

High-level results from the Phase III THALES trial showed AstraZeneca’s Brilinta (ticagrelor) 90mg used twice daily and taken with aspirin for 30 days, reached a statistically significant and clinically meaningful reduction in the risk of the primary composite endpoint of stroke and death, compared to aspirin alone.

Nyhetsarkiv